Recent Work
  • Laboratory Corporation of America, as Canadian Counsel, in its US$1.2B share acquisition of Chiltern International Group Limited.
  • Repare Therapeutics Inc. in connection with the US$68M equity investment in Repare by Versant Ventures and MPM Capital, and backed by U.S. drug giant Celgene Corp. and Canadian investors Fonds de solidarité FTQ and BDC Capital.
  • Norgine B.V. in its acquisition of all of the issued and outstanding common shares of Merus Labs International Inc for approximately C$342M.
  • IRIS The Visual Group with its sale to New Look Vision Group Inc by way of a plan of arrangement, including reviewing the various environmental reports and negotiating the representations, warranties, indemnities and insurance provisions to address the environmental concerns found in due diligence.
  • A clinical stage company that is researching and developing novel vaccine therapies in the drafting of research and development agreements, service agreements and material transfer agreements with universities worldwide, research institutes and government entities, such as Canada’s National Research Council.
  • Akumin Inc. in connection with an initial public offering of common shares issuable without payment upon the deemed exercise of previously issued special warrants.
  • Lumira Capital in its investment in shares of Edesa Biotech Inc. along with Pharmascience Inc., Inveready Technology Investment Group and a number of Canadian family offices for an aggregate C$7M.
  • Kilmer Capital Partners Limited in the sale of Altasciences Company Inc., formerly known as Algorithme Pharma Inc., to the Audax Group.
  • Centric Health Corporation in connection with a senior secured credit facilities of up to C$100M and subordinated credit facility of C$13.5M.
  • ProMetic Life Sciences Inc. in its acquisition of Telesta Therapeutics Inc., a Montréal-based biotechnology company focused on the licensing, acquisition and development of transformational therapeutics for the treatment of serious human diseases such as cancer, immune diseases and targeted rare diseases.
  • The Persistence Capital Partners group, a Canadian private equity firm exclusively focused in healthcare, in transactions with: Anima-Plus Group Inc., Quebec’s leading group of veterinary services providers; LMC Diabetes & Endocrinology, Canada’s leading national diabetes, endocrinology and metabolic disease practice; Plexo Medical Centre, a Quebec-based provider of corporate health services; Copeman Healthcare Inc., a Vancouver-based provider of health services; mdBriefCase Group Inc., Canada and Australia's leading provider of online continuing health education.
  • Tenex Capital Partners, L.P., an operationally focused private equity firm, as Canadian counsel, in its acquisition of the assets of Ohio Medical Corporation from MVC Capital Inc. Ohio Medical Corporation is a market leading manufacturer and distributor of medical suction and oxygen therapy products and source equipment.
  • Dynacare, one of Canada’s largest laboratory services and solutions providers, in a series of strategic acquisitions in various provinces including Lab Bio-Médic, a privately owned laboratory in Quebec that provides services to medical clinics, industries, insurance companies and clinical research organizations; (ii) MedAxio Insurance Medical Services and Warnex Medical Laboratories.
  • A private equity firm in a partnership between IntegraMed Fertility and Groupe OPMEDIC, leading networks of fertility clinics in the United States and Canada, a transaction designed to increase the level of investment and resources available to doctors and patients to deliver outstanding patient outcomes and care.
  • Nordion Inc. in its US$727M acquisition by Sterigenics, a global leader in sterilization services and a portfolio company of GTCR LLC, a leading private equity firm based in Chicago, Illinois, USA.
  • Actavis plc, as Canadian counsel, in two separate transactions: (i) the acquisition by AstraZeneca of Actavis’ branded respiratory business; (ii) the acquisition by TPG of Actavis’ Pharmatech business, a pharmaceutical outsourcing and R&D business within Actavis’ subsidiary Aptalis.
  • Allergan Inc., maker of the Botox wrinkle treatment, as Canadian counsel in its US$66B sale to Actavis plc.
  • Lasik MD Inc. in connection with the C$25M initial investment in Lasik by Caisse de dépôt et placement du Québec as part of Lasik’s long-term financing strategy to assist it in pursuing international acquisitions.
  • LabCorp in its US$6.1B acquisition of Covance, a global drug development services company.
  • Centric Health Corporation acquisition of Pharmacare Fulfillment Center Ltd., an Edmonton-based leading specialty pharmacy business operating under the Care Plus, Pharmacare and Lidia's Pharmacy brands that provides medication dispensing services and clinical care programs to long-term care and retirement community residents across western Canada.